BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 16.6

Change

+0.21 (+1.28)%

Market Cap

USD 1.50B

Volume

0.27M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-30 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

+0.13 (+0.55%)

USD 148.52B
PRS Prudential Financial Inc

+0.24 (+1.01%)

USD 44.13B
ALL-PB The Allstate Corporation

+0.05 (+0.19%)

USD 33.41B
SOJC Southern Co

+0.09 (+0.40%)

USD 21.85B
AIZN Assurant Inc

-0.04 (-0.19%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.20 (+0.81%)

USD 8.69B
PCG-PA Pacific Gas and Electric Compa..

-0.55 (-2.33%)

USD 6.30B
PCG-PB Pacific Gas and Electric Compa..

-0.04 (-0.17%)

USD 5.49B
UNMA Unum Group

+0.22 (+0.92%)

USD 5.28B
PCG-PE Pacific Gas and Electric Compa..

-0.83 (-4.38%)

USD 5.00B

ETFs Containing BMEZ

YYY Amplify High Income ETF 2.95 % 0.50 %

-0.04 (-0.34%)

USD 0.55B
PCEF Invesco CEF Income Compos.. 0.00 % 0.50 %

+0.11 (+-0.34%)

USD 0.81B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.28% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.28% N/A N/A 95% A
Trailing 12 Months  
Capital Gain 6.07% N/A N/A 50% F
Dividend Return 9.08% N/A N/A 92% A
Total Return 15.15% N/A N/A 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.71% N/A N/A 11% F
Dividend Return 0.77% N/A N/A 25% F
Total Return 6.48% N/A N/A 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 24.87% N/A N/A 44% F
Risk Adjusted Return 3.10% N/A N/A 22% F
Market Capitalization 1.50B N/A N/A 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike